Pharmaceuticals & Therapeutics

With FDA Priority Review, Takeda's oveporexton could be the first drug to target the root cause of narcolepsy, offering transformative hope for patients.

Laurie Ann Goldman, the branding guru who built SPANX, is now CEO of Audien Hearing. Can she make affordable hearing aids a mainstream wellness product?

NEXGEL has financing for a major acquisition, but the deal hinges on a critical due diligence phase. What does this mean for the hydrogel innovator?

FibroBiologics' Pete O'Heeron will speak at the H-SPAN summit, highlighting how cell therapy is driving a push for new healthspan legislation.

As Milestone Pharma launches its novel, self-administered heart drug CARDAMYST, it hires a legal expert to navigate the high-stakes commercial rollout.

Ahead of its first Climate Week, Mumbai's food innovators and activists gather to debate a sustainable future, proving the fight for the planet begins on our plates.

Amid major restructuring and a strategic asset sale, Standard BioTools' upcoming annual results will reveal its progress toward profitability in a tough market.

Enanta Pharmaceuticals unveils promising data for EDP-978, an oral drug targeting the root cause of conditions like chronic hives, asthma, and eczema.

Following a landmark FDA approval, IceCure Medical's long-serving CFO is exiting, placing the company at a pivotal financial crossroads for its new treatment.

With transplant patient needs growing, BioMatrix promotes Heidi Ulbrich to manage its services, highlighting a model built for speed and complex care.

The nation's top IV therapy franchise reports record growth, but its expansion highlights a booming wellness industry navigating a complex regulatory landscape.

As Omada Health preps its 2025 results, all eyes are on whether its blend of tech, human coaching, and GLP-1 support can deliver sustainable profits.

With its lead drug in Phase 3, Celldex will update investors at three major conferences, highlighting its immunology pipeline and financial strategy.

Beverly Hills Plastic Surgery® is moving beyond aesthetics with its "Eternal G.L.O.W." series, a year-long program focused on holistic health.

A landmark deal will see Takeda use Iambic's AI platform to slash drug development timelines and fast-track new medicines for cancer and other diseases.

A £500,000 philanthropic investment fuels five pioneering research projects at Oxford, aiming to unlock new treatments for a devastating rare disease.

IN8bio promotes Kate Rochlin to President, signaling a strategic push to advance its promising gamma-delta T cell pipeline amid a challenging market.

New clinical data reveals a minimally invasive spine implant significantly cuts pain, improves function, and reduces opioid use for SI joint dysfunction.

Ernexa Therapeutics secures crucial funding for its cancer therapy pipeline, but the dilutive offering sends its stock plunging more than 50%.

EMD Serono and the Trump Administration launch a new program offering massive discounts on IVF drugs, bringing hope to millions of aspiring parents.